Disease · MONDO_0001330
presbyopia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. presbyopia. Diseases, record MONDO_0001330. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001330
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs15
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PILOCARPINE | CHEMBL550 | Small molecule | Phase 3 | ClinicalTrials.gov | 15 | 15 | 12 | Drugs and targets |
| ACECLIDINE | CHEMBL20835 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| BRIMONIDINE | CHEMBL844 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| PILOCARPINE HYDROCHLORIDE | CHEMBL1200330 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| CARBACHOL | CHEMBL14 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CILMOSTIM | CHEMBL2108239 | Protein | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| PHENTOLAMINE | CHEMBL597 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BRIMONIDINE TARTRATE | CHEMBL1200389 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| VEHICLE | CHEMBL2108661 | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets | |
| OXYMETAZOLINE HYDROCHLORIDE | CHEMBL1200791 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 15
See all 15 drugsTargets10
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRA2A | Adrenergic receptor alpha | 5 | Adrenergic receptor alpha agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha | 5 | Adrenergic receptor alpha agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha | 5 | Adrenergic receptor alpha agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/152 | Drugs and targets |
| CHRM3 | Muscarinic acetylcholine receptor M3 | 4 | Muscarinic acetylcholine receptor M3 agonist; Muscarinic acetylcholine receptor M3 antagonist | Phase 3 | https://conductscience.org/library/genes/1131 | Drugs and targets |
| ADRA1A | Adrenergic receptor alpha | 3 | Adrenergic receptor alpha agonist; Adrenergic receptor alpha antagonist | Phase 3 | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha | 3 | Adrenergic receptor alpha agonist; Adrenergic receptor alpha antagonist | Phase 3 | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha | 3 | Adrenergic receptor alpha agonist; Adrenergic receptor alpha antagonist | Phase 3 | https://conductscience.org/library/genes/146 | Drugs and targets |
| CHRM1 | Muscarinic acetylcholine receptor M1 | 2 | Muscarinic acetylcholine receptor M1 agonist | Phase 3 | https://conductscience.org/library/genes/1128 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 1 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 1 | https://conductscience.org/library/genes/5743 | Drugs and targets |
Trials38
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05656027 | Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia | Phase 3 | 469 | 2026-02-25 | Presbyopia, Refractive Error, Eye Diseases, Near Vision | ACECLIDINE, BRIMONIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT05646719 | Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia | Phase 3 | 333 | 2025-06-03 | Presbyopia | PHENTOLAMINE, PILOCARPINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03804268 | Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia | Phase 3 | 323 | 2021-12-28 | Presbyopia | PILOCARPINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04599933 | An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1) | Phase 3 | 309 | 2023-11-28 | Presbyopia | PILOCARPINE HYDROCHLORIDE, VEHICLE | Its record names the disease | ClinicalTrials.gov |
| NCT04599972 | An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2) | Phase 3 | 304 | 2023-11-28 | Presbyopia | PILOCARPINE HYDROCHLORIDE, VEHICLE | Its record names the disease | ClinicalTrials.gov |
| NCT04806503 | A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia. | Phase 2 | 234 | 2023-08-30 | Presbyopia | ARLIPOIC ACID CHOLINE ESTER CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04983589 | A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily | Phase 3 | 230 | 2023-03-21 | Presbyopia | PILOCARPINE | Its record names the disease | ClinicalTrials.gov |
| NCT05728944 | Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia | Phase 3 | 229 | 2026-02-25 | Presbyopia, Near Vision, Refractive Error, Eye Diseases | ACECLIDINE, BRIMONIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT05270863 | Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia | Phase 3 | 182 | 2024-09-05 | Presbyopia | BRIMONIDINE TARTRATE, CARBACHOL | Its record names the disease | ClinicalTrials.gov |
| NCT05393895 | An Evaluation of the Safety of CSF-1 in Presbyopic Subjects | Phase 3 | 178 | 2025-06-11 | Presbyopia | CILMOSTIM | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsComparisons in its trials21
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pilocarpine HCl Ophthalmic Solution vs Vehicle: deaths from any cause | 0 of 163 | 0 of 160 | 323 | NCT03804268 | Trial comparisons |
| Pilocarpine HCl Ophthalmic Solution vs Vehicle: serious adverse events | 0 of 163 | 0 of 159 | 322 | NCT03804268 | Trial comparisons |
| CSF-1 vs Vehicle: Percentage of Subjects With a ≥ 3-line Gain in BDCVA (Best Distance-Corrected Visual Acuity) at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8, 1 Hour Post-Dose 1. | 60 of 155 | 26 of 154 | 309 | NCT04599933 | Trial comparisons |
| CSF-1 vs Vehicle: Percentage of Subjects With a ≥ 3-line Gain in BDCVA at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8 at 1 Hour Post-Dose 2 | 74 of 155 | 24 of 154 | 309 | NCT04599933 | Trial comparisons |
| CSF-1 vs Vehicle: Percentage of Subjects With a ≥ 3-line Gain in BDCVA at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8 at 2 Hours Post-dose 2 | 60 of 155 | 23 of 154 | 309 | NCT04599933 | Trial comparisons |
| CSF-1 vs Vehicle: deaths from any cause | 0 of 155 | 0 of 154 | 309 | NCT04599933 | Trial comparisons |
| CSF-1 vs Vehicle: Percentage of Subjects With a ≥ 3-line Gain in BDCVA at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8 at 2 Hours Post-Dose 1 | 61 of 155 | 26 of 154 | 309 | NCT04599933 | Trial comparisons |
| CSF-1 vs Vehicle: serious adverse events | 0 of 155 | 1 of 154 | 309 | NCT04599933 | Trial comparisons |
| CSF-1 vs Vehicle: Percentage of Subjects With a ≥ 3-line Gain in BDCVA at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8 at 2 Hours Post-dose 2 | 71 of 154 | 29 of 150 | 304 | NCT04599972 | Trial comparisons |
| CSF-1 vs Vehicle: Percentage of Subjects With a ≥ 3-line Gain in BDCVA at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8 at 1 Hour Post-Dose 2 | 80 of 154 | 25 of 150 | 304 | NCT04599972 | Trial comparisons |
1 to 10 of 21
See all 21 comparisons in its trialsPapers from its trials8
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001330
GET https://conductscience.org/api/diseases/v1/MONDO_0001330/trials?page=2